EUVIMEDEUVIMED entdecken
Open Access

Performance of a whole blood immunoassay for tenofovir detection and correlation with self‐reported pre‐exposure prophylaxis use in HIV ‐negative men who have sex with men interested in blood donation

Renata Buccheri iD, Barbee Whitaker iD, Lance M Pollack, Jahnavi Reddy Bhaskar, Clara Di Germanio iD, Geraldine Guillon, Richard Haaland, Susan L Stramer, Rita Reik, Suchitra Pandey iD, Mars Stone, Steven A Anderson und 2 weitere

Transfusion · 2025

DOI: 10.1111/trf.18275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2025. Verfasst von Renata Buccheri und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Vitalant Research Institute, San Francisco, California, USA. Hauptthemen laut MEDLINE: Tenofovir, Pre-Exposure Prophylaxis, Blood Donors, HIV Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS, FDA HHS, U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In 2023, the United States Food and Drug Administration revised its blood donor eligibility policy for men who have sex with men (MSM) from a 3‐month deferral to individual assessment. Human Immunodeficiency Virus ( HIV) pre‐exposure prophylaxis ( PrEP ) use remains a reason for deferral, and nondisclosure is a concern. Study Design and Methods In a cross‐sectional study of sexually active MSM from 8 U.S. cities who were interested in future blood donation, we assessed the performance of an enzyme‐linked immunosorbent assay for detecting tenofovir ( TFV ) in whole blood ( WB ) and plasma and the correlation with self‐reported PrEP use.

Results

Of 1548 individuals, 48% reported oral PrEP use. The WB assay identified 95% of PrEP users, while the plasma assay detected 88%. The WB assay performed well up to 14 days after the last reported dose. Receiver operating characteristics curve analysis showed an area under the curve of 0.96 (95% confidence interval [ CI] : 0.95–0.97) using WB and 0.88 (95% CI : 0.86–0.90) using plasma. Specificity was 80% for WB and 66% for plasma. Detection rates for TFV disoproxil fumarate/emtricitabine (FTC) formulations were 99% in WB and 98% in plasma, compared to 93% and 86% for the TFV alafenamide/FTC formulation.

Discussion

High concordance between self‐reported oral PrEP use and TFV detection was observed among PrEP users, suggesting the potential utility of WB as a biomatrix for TFV detection to support screening strategies. Given the expanded eligibility for MSM, who may be PrEP users, to donate blood, further examination of undisclosed PrEP use is important.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirPre-Exposure ProphylaxisBlood DonorsHIV InfectionsHomosexuality, MaleAnti-HIV AgentsHumansMaleAdultCross-Sectional StudiesMiddle AgedSelf ReportImmunoassayBlood Donation

Stichwörter der Autor:innen

HIV infectionPrEPadherenceimmunoassaytenofovirwhole blood

Substanzen

TenofovirAnti-HIV Agents

Autor:innen und Institutionen

  • Department of Epidemiology, Vitalant Research Institute, San Francisco, California, USA.
  • Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.
  • Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • OraSure Technologies, Inc., Bethlehem, Pennsylvania, USA.
  • HIV Laboratory Branch, Division of HIV Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • American Red Cross, Scientific Affairs, Gaithersburg, Maryland, USA.

ORCID-Profile: Renata Buccheri, Barbee Whitaker, Clara Di Germanio, Suchitra Pandey, Brian Custer

Förderung

  • Intramural CDC HHS
  • FDA HHS
  • U.S. Food and Drug Administration

Zitieren

APA

Buccheri, R., Whitaker, B., Pollack, L. M., Bhaskar, J. R., Di Germanio, C., Guillon, G., Haaland, R., Stramer, S. L., Reik, R., Pandey, S., Stone, M., Anderson, S. A., Marks, P., & Custer, B. (2025). Performance of a whole blood immunoassay for tenofovir detection and correlation with self‐reported pre‐exposure prophylaxis use in HIV ‐negative men who have sex with men interested in blood donation. Transfusion. https://doi.org/10.1111/trf.18275

Vancouver

Buccheri R, Whitaker B, Pollack LM, Bhaskar JR, Di Germanio C, Guillon G, et al. Performance of a whole blood immunoassay for tenofovir detection and correlation with self‐reported pre‐exposure prophylaxis use in HIV ‐negative men who have sex with men interested in blood donation. Transfusion. 2025. doi:10.1111/trf.18275

BibTeX
@article{Buccheri2025,
  author = {Buccheri, Renata and Whitaker, Barbee and Pollack, Lance M and Bhaskar, Jahnavi Reddy and Di Germanio, Clara and Guillon, Geraldine and Haaland, Richard and Stramer, Susan L and Reik, Rita and Pandey, Suchitra and Stone, Mars and Anderson, Steven A and Marks, Peter and Custer, Brian},
  title = {Performance of a whole blood immunoassay for tenofovir detection and correlation with self‐reported pre‐exposure prophylaxis use in HIV ‐negative men who have sex with men interested in blood donation},
  journal = {Transfusion},
  year = {2025},
  doi = {10.1111/trf.18275}
}
Kostenlos starten →